LivaNova (LIVN) Amortization of Deferred Charges (2019 - 2026)
LivaNova (LIVN) reported Amortization of Deferred Charges of $4.8 million for Q1 2026, down 15.43% on a YoY basis from $5.7 million in Q1 2025, and up 222.08% sequentially from -$3.9 million in Q4 2025.
LivaNova (LIVN) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends
LivaNova (LIVN) has 8 years of Amortization of Deferred Charges data on file, last reported at $4.8 million in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges fell 15.43% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $12.5 million (up 29.71% YoY), and the FY2025 full-year result was $13.4 million, up 51.43% from the prior year.
- Amortization of Deferred Charges advanced to $4.8 million in Q1 2026, from -$3.9 million in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $5.9 million in Q3 2025 to a low of -$6.9 million in Q4 2024.
- A 5-year average of $3.5 million and a median of $4.9 million in 2023 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges surged 89.18% in 2023 and tumbled 242.79% in 2024, its largest moves.
- Tracing LIVN's Amortization of Deferred Charges over 5 years: stood at $4.9 million in 2022, then dropped by 2.69% to $4.8 million in 2023, then plunged by 242.79% to -$6.9 million in 2024, then soared by 42.72% to -$3.9 million in 2025, then jumped by 222.08% to $4.8 million in 2026.
- Business Quant data shows LIVN's Amortization of Deferred Charges at $4.8 million in Q1 2026, -$3.9 million in Q4 2025, and $5.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | LivaNova | 4.40 Bn | 3.86 Bn | 243.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.80 Mn |
| Mar 31, 2026 | 4.80 Mn |
| Dec 31, 2025 | -3.93 Mn |
| Dec 31, 2025 | -3.93 Mn |
| Sep 30, 2025 | 5.90 Mn |
| Sep 30, 2025 | 5.90 Mn |
| Jun 30, 2025 | 5.70 Mn |
| Jun 30, 2025 | 5.70 Mn |
| Mar 31, 2025 | 5.68 Mn |
| Mar 31, 2025 | 5.68 Mn |
| Dec 31, 2024 | -6.86 Mn |
| Dec 31, 2024 | -6.86 Mn |
| Sep 30, 2024 | 5.50 Mn |
| Sep 30, 2024 | 5.50 Mn |
| Jun 30, 2024 | 5.30 Mn |
| Jun 30, 2024 | 5.30 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Dec 31, 2023 | 4.81 Mn |
| Dec 31, 2023 | 4.81 Mn |